Client Work

Sonic Incytes Completes Series A Raise of US$7.3M

Reading Time 1 minute read
Share

Overview

Client

Sonic Incytes Medical Corp.

Sonic Incytes Medical Corp., a health technology company focused on liver health, completed its US$7.3M Series A with backing from Nimbus Synergies as the lead investor, to accelerate VelacurTM, the first handheld 3D liver health assessment solution, commercialisation.

 

Fasken advised Sonic Incytes Medical Corp. with a team led by Geoff Pedlow (Technology) and included Roger A.C. Kuypers (Life Sciences), Brandon Deans (Start Up & Emerging Technology) and Brock Euper (Corporate/Commercial).

Jurisdiction

  • British Columbia

Team

  • Roger A.C. Kuypers, Partner | Trademark Agent | Life Sciences, Vancouver, BC, +1 604 631 4880, rkuypers@fasken.com
  • Geoff Pedlow, Partner | Technology, Media and Telecommunications, Mergers & Acquisitions, Vancouver, BC, +1 604 631 4765, gpedlow@fasken.com
  • Brock Euper, Associate | Corporate/Commercial, Vancouver, BC, +1 604 631 3142, beuper@fasken.com
Roger A.C. Kuypers, Partner | Trademark Agent | Life Sciences Roger A.C. Kuypers Partner | Trademark Agent | Life Sciences Vancouver, BC +1 604 631 4880
Geoff Pedlow, Partner | Technology, Media and Telecommunications, Mergers & Acquisitions Geoff Pedlow Partner | Technology, Media and Telecommunications, Mergers & Acquisitions Vancouver, BC +1 604 631 4765
Brock Euper, Associate | Corporate/Commercial Brock Euper Associate | Corporate/Commercial Vancouver, BC +1 604 631 3142